

Slide 1 Slide 2






Slide 3 Slide 4







Slide 5 Slide 6





Slide 7 Slide 8





Slide 9 Slide 10

• Diseases of the posterior segment are among the leading causes of vision loss worldwide.

- The new frontier:
 - Optometrists have now begun to fully embrace vitreoretinal care.

"Most major advances in the understanding of retinal diseases have been preceded by advances in imaging."

Richard Spaide, MD
NY Retina Consultants

Slide 11 Slide 12


Retinal imaging does


not

replace a dilated retinal examination.




Slide 13 Slide 14





Slide 15 Slide 16






Slide 17 Slide 18





Slide 19 Slide 20





Slide 21 Slide 22







Slide 23 Slide 24







Slide 25 Slide 26






Slide 27 Slide 28







Slide 29 Slide 30






Slide 31 Slide 32






Slide 33 Slide 34





Slide 35 Slide 36






Slide 37 Slide 38


FOR COLOR PPT NOTES...

- Available at:
- https://tinyurl.com/PIZVEE
- Problems downloading? Send an email request for the handouts to allthingsoct@gmail.com.




Slide 39 Slide 40







Slide 41 Slide 42







Slide 43 Slide 44






Slide 45 Slide 46






Slide 47 Slide 48







Slide 49 Slide 50







Slide 51 Slide 52







Slide 53 Slide 54







Slide 55 Slide 56







Slide 57 Slide 58







Slide 59 Slide 60







Slide 61 Slide 62






Slide 63 Slide 64






Slide 65 Slide 66




What is MMI?

- MMI refers to the use of multiple technological systems to acquire images.
- May also include hybrid devices that simultaneously perform 2 or more imaging modalities.
- Images acquired by MMI complement one another clinically.


Slide 67 Slide 68







Slide 69 Slide 70







Slide 71 Slide 72







Slide 73 Slide 74





Slide 75 Slide 76







Slide 77 Slide 78






Slide 79 Slide 80







Slide 81 Slide 82






Slide 83 Slide 84





Slide 85 Slide 86







Slide 87 Slide 88







Slide 89 Slide 90







Slide 91 Slide 92







Slide 93 Slide 94







Slide 95 Slide 96





Slide 97 Slide 98







Slide 99 Slide 100

OCT/OCTA has forever changed the classification, diagnosis, and management of AMD, and especially nAMD.


CC: Worsening central vision OS x 4 wks OC Hx: POAG OU S/p SLT OS x 6 mon, SLT OD x 9 mon Intermediate Dry AMD OU Taking ARED2 Plus supplements VA: OD 20/30 PHNI OS 20/40 PHNI, down from 20/25 four mon prior IOP: 14 OD/13 OS


Slide 101 Slide 102







Slide 103 Slide 104






Slide 105 Slide 106







Slide 107 Slide 108




Unfavorable prognostic signs leading to CNVM, GA • Soft, large, confluent drusen • Reticular (pseudo) drusen* • Focal hyperpigmentation • Disciform lesion in the fellow eye • Older age • Poor dark adaptation*


Slide 109 Slide 110







Slide 111 Slide 112







Slide 113 Slide 114







Slide 115 Slide 116







Slide 117 Slide 118






Slide 119 Slide 120





Slide 121 Slide 122






Slide 123 Slide 124






Slide 125 Slide 126





Slide 127

Tiny Bubbles





Joseph J. Pizzimenti, OD, FAAO

Slide 128


Case History and Clinical Findings

- A 30-year-old male presented with a chief complaint of mild, bilateral central blur of one year's duration.
- · Health history was positive for type 2 diabetes.
- •Best corrected visual acuities were 20/25 at distance and 20/20 at near for both eyes.
- Amsler testing revealed central metamorphopsia in each eye.

Slide 129 Slide 130

Additional Clinical Findings

- Dilated funduscopy showed a honeycomb pattern of pigment epithelial changes within each central retina that resembled small, translucent bubbles.
- Mod NPDR OD, Mild NPDR OS without macula edema.
- Peripheral retina intact and unremarkable OU




Slide 131


Special Testing

- Further investigation through MMI with FAF and OCT confirmed multiple serous RPEDs of various sizes in both eyes spanning 2.5 DD centered around the fovea.
- · Differential Diagnosis
 - · Pattern Dystrophy of RPE
 - · Central Serous Chorioretinopathy
 - * Bilateral Idiopathic Multiple RPE Detachment


Slide 132



Slide 133 Slide 134




OCT-OD: Multiple RPEDs of Varied Size



Slide 135 Slide 136


OCT OS: Multiple RPEDs of Varied Size, Note Slightly Thick Choroid




En Face OCT Showing "Tiny Bubbles"



Slide 137 Slide 138





Slide 139 Slide 140


Discussion


- Bilateral Idiopathic Multiple RPED is a rare presentation that may represent an atypical form of CSC or another pachychoroid syndrome.
 - Pachychoroid Pigment Epitheliopathy
- There is currently no preferred treatment, besides observation, as visual prognosis is typically good.

Conclusion


- Multimodal ophthalmic imaging is useful in ruling out various differential diagnoses, as well as monitoring for progressive changes such as serous RD and MNV.
- MMI was a difference maker in revealing the diagnosis of this case.

Slide 141 Slide 142





Slide 143 Slide 144





HCQ TOXICITY

Perform DFE annually.


What additional testing/work-up is appropriate?


Slide 145 Slide 146







Slide 147 Slide 148







Slide 149 Slide 150







Slide 151 Slide 152







Slide 153 Slide 154






Slide 155 Slide 156






Slide 157 Slide 158



Plaquenil Toxicity

- By the time "flying saucer" or "bullseye" is detected, significant toxic damage has occurred.
- · May progresses even if drug is stopped.
- · Ganglion cell analysis and en face OCT may offer early detection.



Slide 159 Slide 160

What is the recommended maximum HCQ dose? Calculate Max Dose in mg/day 2.3 x weight (in lbs.) = Max dose At recommended dose, risk of toxicity is < 1% after 5 years, < 2% after 10 yrs. Risk rises to almost 20% after 20 years. ** Our patient VY (~110-120 lbs) was taking 400 mg/d for 20 yrs Risk for HCQ maculopathy depends on daily dose, duration of use

AMERICAN ACADEMY

American Academy of Ophthalmology Statement

Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)

Michael F. Marmor, MD, ¹ Ulsich Kellner, MD, ² Timothy Y.Y. Lai, MD, FRCOphin, ¹ Ronald B. Melles, MD, ⁴ Williams F. Micler, MD, ² for the American Academy of Ophthalmology


Background: The American Academy of Ophthalmology recommendations on screening for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, landus distribution, and effectiveness of screening toxic.

Pattern of Retinopathy: Although the locus of toxic damage is parafloveal in many eyes, Asian patients othen show an extramacular pattern of damage.

Dose: We recommend a maximum daily HCQ use of ≤5.0 mg/kg real weight, which correlates better with risk than ideal weight. There are no similar demographic data for CQ, but dose comparisons in older Herature suggest using ≤2.3 mg/kg real weight.


Risk of Toxicity: The risk of toxicity is dependent on daily dose and duration of use. At recommended doses, the risk of Toxicity: The risk of toxicity is dependent on daily dose and duration of use. At recommended doses, the risk of Toxicity: The risk of toxicity is dependent on daily dose and duration of use. At recommended doses, the risk of Toxicity: The risk of toxicity is a patient without toxicity has only a 4% risk of converting in the subsequent year.


Slide 161 Slide 162





Slide 163 Slide 164





Slide 165 Slide 166



Plaquenil Maculopathy

- Testing for patients on Plaquenil
 - DFE
 - VF 10-2 W/W (add 24-2 or 30-2 in Asians)
 - SD or SS-OCT: raster and cube scans
 - FAF
 - mfERG
- Increase frequency of monitoring (2+ visits per year) w/degree of pathophysiology.

Slide 167 Slide 168


Summary and Case Outcome

- MMI and other diagnostics are essential in evaluation of patients using CQ or HCQ on a chronic basis.
- Co-management team includes:
- Optometry
- Rheumatology
 - Other therapies: methotrexate, TNF inhibitors (our patient VY was switched to this drug class)




Slide 169 Slide 170







Slide 171 Slide 172



Olifferential Diagnoses Macular Telangiectasia (Type 2) Age related macular degeneration (AMD)—only 57 y/o Previous Branch Retinal Vein Occlusion (BRVO) w/old ME Diabetic Retinopathy w/old ME, now mac ischemia Previous Central Serous Chorioretinopathy (CSC) Pattern Dystrophy of the RPE


Slide 173 Slide 174







Slide 175 Slide 176

OCTA- OD OCT-Angiography of OD highlights temporal perifoveal telangiectasias in the superficial, deep, and even avascular layers of the retina. These particular telangectatic vessels appear deeper than usual.




Slide 177 Slide 178






Slide 179



Slide 180



Slide 181 Slide 182


Treatment/Discussion. Anti-VEGF therapy is the most promising treatment for Mactel with SRN. New research suggests that Anti-VEGF agents improve structure in Mactel both with and without SRN, but functional gain is limited to eyes with proliferation. It is important to monitor eyes with Mactel every 4-6 months for SRN development. Conclusion. OCT-A aids in the diagnosis of MT and may enable earlier detection of SRN.




Slide 183

TYPES OF MACTEL Type I Perhaps a mild form of Costs disease. Like Costs, these potients are typically male and have a unilateral presentation. Exudates, here. Changes are more often localized to the miscula and paramacular area than is seen in Costs disease. Type 2 Male or female and usually have a bibberal presentation. This form is associated with minimal to no lipid exudation and demonstrates superficial retinal crystals in approximately 50% of patients. Pigment hyperplasia, migration and plaque formation can be seen in the later stages. Type 3 This type is exceedingly rare. Capillary occlusions are a halfmark sign.

Slide 184




Slide 185 Slide 186







Slide 187 Slide 188

WH CLASSIFICATION & MANAGEMENT The International Vitreomacular Traction Study (IVTS) Group formed a classification scheme for VMT and macular holes based on OCT findings: Vitreomacular adhesion (VMA): No distortion of foveal contour; size of attachment area between hyaloid and retina defined as focal if </ = 1500 microns and broad if >1500 microns Vitreomacular traction (VMT): Distortion of foveal contour present or intraretinal structural changes in the absence of a full-hickness macular hole; focal if </ = 1500 microns and broad if >1500 microns Date JR, Nater PR, Brider S, et al. The International Vitreomacular Traction Study Group Classification of Vitreomacular Adhesion, Traction, and Macular Hole. Ophthalmology. 2015; 120:2511-2515.





Slide 189 Slide 190






Slide 191 Slide 192






Slide 193 Slide 194



WHAT IS SWEPT SOURCE OCT?


- A second type of Fourier Domainbased OCT.
 - The other FD-OCT is Spectral Domain (SD-OCT)*
- SS-OCT
 - Twice as fast (twice as many A-scans / second) as SD-OCT.
 - Allows for wide field imaging (12 mm vs 6-9 mm).
 Easily captures ONH and macula in same scan.
 - Uses a longer wavelength, so can image much more effectively through media opacities, and penetrate deeper into the choroid (2.6 mm depth vs. 2.3 mm).


Slide 195 Slide 196





Slide 197 Slide 198





Slide 199 Slide 200

Summary

- Contemporary OCT and OCTA provides valuable information about tissue morphology, retinal/choroidal vasculature, and stability versus progression of disease.
- This information, combined with history, DFE, MMI and functional testing, enables clinicians to establish accurate diagnoses and make better-informed decisions.

CONCLUSION

- OCT, OCTA, and MMI have revolutionized posterior segment care.
- Indeed OCT has forever changed retina!

Slide 201 Slide 202



